期刊文献+

肾上腺肿瘤P53及c-myc癌基因表达研究 被引量:1

Expression of P53 and c myc gene in human adrenal tumors
原文传递
导出
摘要 为探讨肾上腺肿瘤发病机理,为鉴别肿瘤良恶性及其分级分期提供依据,收集34例肾上腺恶性肿瘤应用SP法作P53及cmyc免疫组化检测,并与25例肾上腺良性瘤及12例非瘤肾上腺组织对比。结果显示:肾上腺恶性瘤P53阳性率471%,良性瘤80%,非瘤组织无表达;肾上腺恶性肿瘤cmyc阳性率382%,良性瘤及非瘤组织无表达;P53表达与肾上腺恶性瘤临床分期相关,cmyc与其临床分期不相关,均可用于良恶性瘤鉴别。 Detection of P53 and c myc with immunohistochemical technique were carried out for 34 surgical specimens of malignant tumor of adrenal gland,25 adrenal benign tumors and in 12 adrenal tissues free of tumor.The positive rate of P53 expression was 47.1% in adrenal malignant tumors,8 0% in benign tumors but none in adrenal tissues free of tumor.c myc expression was positive in 38.2% of malignant tumors but none in either benign tumors or adrenal tissues free of tumor.P53 expression was related to the clinical stage of adrenal maligmant tumors while c myc did not.The detection of the two might help in the differentiation of malignant from benign adrenal tumors.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 1997年第1期30-32,共3页 Chinese Journal of Urology
关键词 肾上腺肿瘤 癌基因 P53 C-MYC 表达 Adrenal neoplasms Genes
  • 相关文献

参考文献3

  • 1牛天力,中华泌尿外科杂志,1996年,17卷,14页
  • 2Lin Shiuru,J Clin Endocrinol Metab,1994年,78卷,483页
  • 3俞天麟,现代泌尿外科,1989年,87页

同被引文献37

  • 1Dackiw AP, Lee JE, Gagel RF, et al. Adrenal cortical carcinoma [J]. World J Surg, 2001, 25: 914-926.
  • 2Herrmann LJ, Heinze B, Fassnacht M, et al. TP53 germline mu- tations in adult patients with adrenocortical carcinoma [ J]. J Clin Endocrinol Metab, 2012, 97: E476-E485.
  • 3Samani AA, Yakar S, Leroith D, et al. The role of the IGF sys- tem in cancer growth and metastasis : overview and recent insights [ J]. Endocr Rev, 2007, 28: 20-47.
  • 4Maher ER, Reik W. Beckwith-Wiedemann syndrome: imprinting in clusters revisited [J]. J Clin Invest, 2000, 105: 247-252.
  • 5Zwermann O, Beuschlein F, Mora P, et al. Multiple endocrine neoplasia type 1 gene expression is normal in sporadic adrenocor- tical tumors [J]. Eur J Endocrinol, 2000, 142: 689-695.
  • 6Berruti A, Ferrero A, Sperone P, et al. Emerging drugs for adre- nocortical carcinoma [ J]. Expert Opin Emerg Drugs, 2008, 13: 497-509.
  • 7Gombos A, Metzger-Filho O, Dal Lago L, et al. Clinical devel- opment of insulin-like growth factor receptor-1 (IGF-1R) inhibi- tors: at the crossroad? [ J]. Invest New Drugs, 2012, 30: 2433- 2442.
  • 8de Fraipont F, E1 Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortieal tumors using complementary de- oxyribonucleic Acid mieroarrays identifies several candidate genes as markers of malignancy [ J ]. J Clin Endoerinol Metab, 2005, 90: 1819-1829.
  • 9Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitu- mumab in patients with refractory adrenoeortieal carcinoma [ J]. Cancer Chemother Pharmacol, 2010, 65: 765-773.
  • 10Naing A, Lorusso P, Fu S, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR in- hibitor temsirolimus in patients with metastatic adrenoeortical car- cinoma [J]. Br J Cancer, 2013, 108: 826-830.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部